Valuation: Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Market Cap 12.05B 1.81B 1.62B 1.49B 1.35B 2.53B 172B 2.57B 17.83B 7.11B 90.11B 6.79B 6.64B 285B P/E 2026 *
18.2x
P/E 2027 * 15.1x
Enterprise Value 9.71B 1.46B 1.31B 1.2B 1.09B 2.04B 139B 2.07B 14.37B 5.73B 72.64B 5.47B 5.35B 230B EV / Sales 2026 *
1.9x
EV / Sales 2027 * 2.32x
Free-Float
14.94%
Yield 2026 *
0.66%
Yield 2027 * 0.77%
08-28 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-26 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Ordinary Final Dividend on A Shares for the Year Ended December 31, 2025, Payable on 18 June 2026 CI
05-22 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Board Changes CI
04-30 Shenzhen Hepalink Pharmaceutical's Profit Rises 20% in Q1 MT
04-29 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-30 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Proposes Final Ordinary Cash Dividend for the Year Ended 31 December 2025, Payable on 22 July 2026 CI
03-30 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-30 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2025 CI
01-30 Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025 MT
12-16 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves the Election of Pu Hong as Independent Non-Executive Director, Effective December 16, 2025 CI
11-24 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Retirement of Chuan Lu from the Board CI
30/10/25 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/08/25 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
1 day-1.41%
1 week-2.68%
Current month-7.82%
1 month-6.00%
3 months-4.72%
6 months-15.77%
Current year-22.99%
1 week 8.95
Extreme 8.95
9.42
1 month 8.95
Extreme 8.95
10
Current year 8.5
Extreme 8.5
12.64
1 year 8.5
Extreme 8.5
12.68
3 years 6.89
Extreme 6.89
14.34
5 years 6.89
Extreme 6.89
18.89
10 years 6.89
Extreme 6.89
30.69
Manager TitleAgeSince
Chief Executive Officer 65 20/04/1998
Corporate Officer/Principal 61 20/04/1998
Director of Finance/CFO 51 20/08/2023
Director TitleAgeSince
Director/Board Member 61 20/04/1998
Director/Board Member 76 21/05/2023
Director/Board Member 69 15/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
23/05/23 Sell 11,200 0.0009%
26/05/21 Other

Chief Financial Officer

459,588 0.2088%
Change 5-day change 1-year change 3-year change Capi.($)
-1.41%-2.68%-23.89%-25.63% 1.83B
+6.07%+4.75%+68.26%+141.96% 1,148B
+1.20%+2.47%+46.95%+86.50% 652B
+1.04%+1.25%+28.26%+103.51% 505B
+0.73%+2.45%+54.26%+66.47% 384B
+4.40%-0.27%+69.60%+43.01% 348B
+2.38%+2.65%+34.31%+56.33% 294B
+2.26%+0.55%+3.92%+27.74% 264B
+1.53%+2.38%+56.95%+73.99% 244B
+1.41%+2.68%+36.20%+107.54% 197B
Average +2.00%+1.04%+37.48%+68.14% 403.9B
Weighted average by Cap. +3.01%+1.50%+49.63%+92.94%

Financials

2026 *2027 *
Net sales 5.1B 766M 686M 633M 573M 1.07B 72.94B 1.09B 7.55B 3.01B 38.17B 2.87B 2.81B 121B 5.62B 843M 755M 696M 630M 1.18B 80.25B 1.2B 8.31B 3.31B 42B 3.16B 3.1B 133B
Net income 731M 110M 98.19M 90.59M 81.98M 153M 10.44B 156M 1.08B 431M 5.46B 411M 403M 17.3B 874M 131M 117M 108M 98.04M 183M 12.49B 186M 1.29B 516M 6.53B 492M 482M 20.7B
Net Debt -2.34B -351M -314M -290M -262M -490M -33.4B -498M -3.46B -1.38B -17.48B -1.32B -1.29B -55.36B 1B 151M 135M 124M 113M 211M 14.34B 214M 1.48B 592M 7.51B 565M 553M 23.77B
Projected Income Statement - Annual - Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Logo Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the heparin industry chain, contract development and manufacturing organization (CDMO) of biological macromolecules, and the investment, development, and commercialization of innovative drugs. The Company operates four segments. The Pharmaceutical Formulations segment manufactures and sells enoxaparin sodium injection and others. The Active Pharmaceutical Ingredients (APIs) segment manufactures and sells standard heparin APIs, enoxaparin APIs and others. The CDMO segment provides process development services for pharmaceutical intermediates and APIs, including process research, optimization, analytical testing, and formulation research. The Other segment engages in other product businesses, such as pancreatic enzymes and casings. The Company conducts its business in the domestic and overseas markets.
Employees
2,150
Date Price Change Volume
28/10/26 CN¥9.080 -1.41% 2,004,000
28/10/26 CN¥9.210 +1.66% 3,028,400
27/10/26 CN¥9.060 -3.10% 2,845,800
26/10/26 CN¥9.350 +0.86% 3,079,900
23/10/26 CN¥9.270 +1.42% 3,102,200
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
9.080CNY
Average target price
7.500CNY
Spread / Average Target
-17.40%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 002399 Stock